Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

BENZALDEHYDE CRS (150 MG)

BENZALDEHYDE CRS (150 MG)

100-52-7

DISCOVER
BETAMETHASONE VALERATE IMPURITY MIXTURE CRS (0.018 MG)

BETAMETHASONE VALERATE IMPURITY MIXTURE CRS (0.018 MG)

NA

DISCOVER
Simvastatin for peak identification

Simvastatin for peak identification

79902-63-9

DISCOVER
AMLODIPINE FOR PEAK IDENTIFICATION CRS (10 MG)

AMLODIPINE FOR PEAK IDENTIFICATION CRS (10 MG)

111470-99-6

DISCOVER
AMLODIPINE IMPURITY A CRS (15MG)

AMLODIPINE IMPURITY A CRS (15MG)

NA

DISCOVER
AMLODIPINE IMPURITY B CRS (15MG)

AMLODIPINE IMPURITY B CRS (15MG)

NA

DISCOVER
AMLODIPINE IMPURITY G CRS (10MG)

AMLODIPINE IMPURITY G CRS (10MG)

NA

DISCOVER
BENSERAZIDE IMPURITY C CRS (15 MG)

BENSERAZIDE IMPURITY C CRS (15 MG)

NA

DISCOVER
LOSARTAN IMPURITY D CRS (10 MG)

LOSARTAN IMPURITY D CRS (10 MG)

83857-96-9

DISCOVER
BECLOMETASONE  DIPROPIONATE IMPURITIES F AND N CRS (0.052 MG

BECLOMETASONE DIPROPIONATE IMPURITIES F AND N CRS (0.052 MG

NA

DISCOVER
RIFAXIMIN CRS (160 MG)

RIFAXIMIN CRS (160 MG)

80621-81-4

DISCOVER
RIFAXIMIN FOR SYSTEM SUITABILITY CRS (10 MG)

RIFAXIMIN FOR SYSTEM SUITABILITY CRS (10 MG)

80621-81-4

DISCOVER